1. Workowski KA, Berman S. Pelvic inflammatory disease treatment guidelines. In: Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR Recomm Rep. 2010. 59(RR-12):63–67.
2. Crossman SH. The challenge of pelvic inflammatory disease. Am Fam Physician. 2006. 73:859–864.
3. Timor-Tritsch IE, Lerner JP, Monteagudo A, Murphy KE, Heller DS. Transvaginal sonographic markers of tubal inflammatory disease. Ultrasound Obstet Gynecol. 1998. 12:56–66.
Article
4. Ness RB, Soper DE, Holley RI, Peipert J, Randall H, Sweet RI, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the pelvic inflammatory disease evaluation and clinical health (PEACH) randomized trial. Am J Obstet Gynecol. 2002. 186:929–937.
Article
5. Haggerty CL, Taylor BD. Mycoplasma genitalium: An emerging cause of pelvic inflammatory disease. Infect Dis Obstet Gynecol. 2011. 2011:–959816.
Article
6. Larsen B, Hwang J. Mycoplasma, Ureaplasma, and Adverse Pregnancy Outcomes: A Fresh Look. Infect Dis Obstet Gynecol. 2010. 2010:–pii: 521921.
7. Baczynska A, Svenstrup HF, Fedder J, Birkelund S, Christiansen G. Development of real-time PCR for detection of Mycoplasma hominis. BMC Microbiol. 2004. 4:35.
8. Yudin MH, Hillier SL, Wiesenfeld HC, Krohn MA, Amortegui AA, Sweet RI. Vaginal polymorphonuclear leukocytes and bacterial vaginosis as markers for histologic endometritis among women without symptoms of pelvic inflammatory disease. Am J Obstet Gynecol. 2003. 188:318–323.
Article
9. Heo H, Ha JY, Kim KW, Lee DK, Kim DG, Yang HS, et al. A report of pelvic inflammatory disease in the region of the Po-Hang. Korean J Obstet Gynecol. 2003. 46:1116–1120.
10. Sorbye IK, Jerve F, Staff AC. Reduction in hospitalized women with pelvic inflammatory disease in Oslo over the past decade. Acta Obstet Gynecol Scand. 2005. 84:290–296.
Article
11. Simms I, Eastick K, Mallinson H, Thomas K, Gokhale R, Hay P, et al. Associations between
Mycoplasma genitalium,
Chlamydia trachomatis and pelvic inflammatory disease. J Clin Pathol. 2003. 56:616–618.
Article
12. Cho MK. Update on the management of pelvic inflammatory disease. Korean J Obstet Gynecol. 2010. 53:961–966.
Article
13. Bae HG, Heo WB, Lee NY, Lee WK, Koo TB. Detection of Ureaplasma urealyticum and Mycoplasma hominis in pregnant women using MYCOFAST® Evolution 2 and PCR. Korean J Clin Microbiol. 2003. 6:74–80.
14. Lee HH, Lee KH, Ju KS, Won NH. Detection of Chlamydia trachomatis, Mycoplasma hominis and Ureaplasma urealyticum in the cervical swab and paraffin tissue with female genital tract infection. Korean J Obstet Gynecol. 1999. 42:549–555.
15. Yu N, Lee MK. Clinical implications of multiplex PCR detection of fastidious microorganisms in vaginitis patients. Korean J Clin Microbiol. 2011. 14:30–35.
Article
16. Shin JS, Park CH, Yoo EH, Lee SG. Leukocytes and lactobacilli of vaginal discharge as a predictor of pelvic inflammatory disease. Korean J Obstet Gynecol. 2007. 50:1247–1253.
17. Brunham RC, Binns B, Guijon F. Etiology and outcome of acute pelvic inflammatory disease. J Infect Dis. 1988. 158:510–517.
Article
18. Oskarsson T, Geirsson RT, Steingrimsson O, Thorarinsson H. Lower genital tract infection with
Neisseria gonorrhoeae and
Chlamydia trachomatis in women requesting induced abortion and in their sexual partners. Acta Obstet Gynecol Scand. 1990. 69:635–640.
Article
19. Peipert JF, Ness RB, Blume J, Soper DE, Holley R, Randall H, et al. Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. Am J Obstet Gynecol. 2001. 184:856–863.
Article
20. Clarke IN. Evolution of Chlamydia trachomatis. Ann N Y Acad Sci. 2011. 1230:E11–E18.